HCA Healthcare, Inc. (HCA) $467.83
HCA Healthcare is currently navigating treacherous waters, with its stock price plunging into deeply oversold territory, yet caught in a relentless downtrend.
52-wk High $556.52
📌 Investment Snapshot
- 💰 HCA trades at $467.83, commanding a 16.7x P/E multiple against its $28.07 TTM EPS.
- 📈 Q4 2025 revenue hit $19.51B, with EPS at $8.09, demonstrating consistent top-line growth.
- 🔑 Insider buying in February 2026 signals management confidence despite recent price weakness.
- 🎯 Analysts maintain a Buy rating with a mean target of $543.05, implying 16.1% upside.
HCA Healthcare currently trades at $467.83, deeply oversold with an RSI of 1.5, yet it remains in a strong downtrend as indicated by ADX and MACD. The stock has fallen over 11% in the last month, testing critical support levels. While the technical confluence score is moderate at 70/100, the lack of sufficient consensus upside (16.1% vs. 25% threshold for large caps) and persistent bearish momentum prevent a ‘Buy’ call.
| 📍 Entry Zone | $460.00 or below | 🛑 Stop-Loss | $425.00 |
| 📋 Adjust If | Price reclaims $480.00 with sustained volume above 1.5x average, signaling a potential reversal and filling the nearest bearish FVG. | ||
The Investment Case — Why Now?
HCA Healthcare finds itself at a critical juncture, having shed over 11% in the last month to trade at $467.83. This sharp decline has pushed its 14-day RSI to an extreme 1.5, screaming deeply oversold conditions. Despite this technical capitulation, the company continues to deliver robust financial performance, highlighted by consistent revenue growth and significant insider buying in February.
However, the primary risk challenging an immediate entry is the stock’s persistent bearish momentum, confirmed by a high ADX reading and a deeply negative MACD. This strong downtrend, coupled with a high VIX and a declining S&P 500, suggests that HCA could experience further capitulation before finding a definitive bottom. We need clear technical confirmation of a reversal before committing capital.
🤔 Given the conflicting signals of extreme oversold conditions and strong bearish momentum, what specific technical indicator would you prioritize for a definitive entry signal?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | HCA Healthcare, Inc. |
| Ticker / Exchange | HCA / NYSE |
| Sector / Industry | Healthcare | Medical Care Facilities |
| CEO | |
| Founded / HQ |
📈 Price Action & Technicals
Dead Cross
Inside VA
Sell-side Sweep at $546.62 on 2026-03-12, indicating significant selling pressure at higher levels.
HCA’s price action reveals a stock under significant pressure. It currently trades below its 50-day Simple Moving Average ($508.68), which now acts as overhead resistance, though it remains above the longer-term 200-day SMA ($445.07). This suggests a breakdown in short-term momentum while the long-term trend remains somewhat intact.
The 14-day RSI at an alarming 1.5 screams extremely oversold, signaling potential for a bounce. However, the MACD’s deep negative reading (-12.12) below its signal line (-5.7) confirms strong bearish momentum, while the ADX at 29.5 with a dominant -DI (37.1) over +DI (8.6) unequivocally points to a robust downtrend. This contradiction between an oversold condition and sustained bearish trend demands caution.
The stock is currently trading just below the Volume Profile’s Point of Control (POC) at $469.33, indicating it’s at a high-volume node where significant price discovery has occurred. While the price remains above the Anchored VWAP from April 2025 ($425.84), this level could serve as a critical support if the current selling pressure intensifies.
Volume is running well below average at 48% of its 20-day average, suggesting a lack of conviction from buyers even at these depressed levels. The price sits near the lower Bollinger Band ($460.29), a level that often precedes a mean reversion bounce. However, recent sell-side liquidity sweeps at higher prices confirm institutional distribution, and multiple unfilled bearish Fair Value Gaps (FVGs) above the current price could act as resistance zones on any attempted rally.
🤔 With HCA’s RSI at 1.5, indicating extreme oversold conditions, why isn’t this a definitive ‘Buy’ signal for short-term traders?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| HCA | HCA Healthcare, Inc. | 16.7x |
| CNC | Centene Corp. | 12.5x |
| UHS | Universal Health Services | 15.8x |
| LH | Labcorp | 18.2x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $19.51B | $8.09 | |
| Q3 2025 | $19.16B | $6.96 | |
| Q2 2025 | $18.61B | $6.83 | |
| Q1 2025 | $18.32B | $6.45 |
HCA generated $0.9B in Free Cash Flow in the latest quarter, demonstrating robust operational efficiency. The company actively returned capital to shareholders, executing $2.6B in share buybacks during the same period, signaling confidence in its intrinsic value.
🚀 Growth Drivers — What Moves the Stock
- Demographic Tailwinds 🟡 Priced In — The aging U.S. population continues to drive increasing demand for healthcare services, providing a structural tailwind for HCA’s extensive network of hospitals and facilities.
- Operational Efficiency & Scale 🟡 Priced In — As one of the largest healthcare providers, HCA benefits from significant economies of scale, allowing for better cost management and stronger negotiating power with suppliers and payers.
- Strategic Market Expansion 🟢 Upside Surprise — HCA’s ongoing investments in high-growth markets and specialized service lines position it to capture a larger share of the evolving healthcare landscape.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 14,716 |
| Blackrock Inc. | 12,581 |
| Sanders Capital, LLC | 10,464 |
| State Street Corporation | 7,566 |
| Capital World Investors | 4,999 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| MCALEVEY MICHAEL R. | Officer | Feb 18, 2026 | Purchase | 1,694 |
| MCALEVEY MICHAEL R. | Officer | Feb 13, 2026 | Purchase | 5,000 |
| BERRES JENNIFER | Officer | Feb 11, 2026 | Purchase | 8,020 |
| WYATT CHRISTOPHER F | Officer | Feb 11, 2026 | Purchase | 4,000 |
| WYATT CHRISTOPHER F | Officer | Feb 10, 2026 | Purchase | 3,350 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 3.1 |
⚠ Key Risk Factors
~$10B market cap impact
~5% EPS impact
~$1B revenue impact
~2% revenue impact
🤔 With a high VIX and S&P 500 decline, how much of HCA’s recent drop is attributable to broader market sentiment versus company-specific concerns?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $635.0 | $543.05 | $425.0 | 21 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| TD Cowen | Buy | Mar 2026 | Maintains | |
| Mizuho | Outperform | Feb 2026 | Maintains | |
| UBS | Buy | Feb 2026 | Maintains | |
| JP Morgan | Neutral | Feb 2026 | Maintains | |
| Argus Research | Buy | Feb 2026 | Maintains |
The analyst consensus leans heavily towards a Buy rating, with the majority maintaining positive outlooks. However, the mean price target of $543.05 suggests a 16.1% upside, which, while positive, falls short of the 25% threshold typically sought for a high-conviction ‘Buy’ in a large-cap stock.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- HCA’s RSI at 1.5 indicates extreme oversold conditions, historically preceding significant bounces.
- Consistent insider buying by multiple officers signals strong internal confidence in the company’s future prospects.
- Robust quarterly revenue growth and significant share buybacks underscore solid financial health and shareholder value creation.
📊 Base Case
Our base case assumes HCA will consolidate around current levels, experiencing short-term volatility due to market conditions. The company’s strong fundamentals will provide a floor, but the prevailing bearish technicals and macro headwinds will cap any immediate upside. We project a fair value around the consensus target, reflecting continued steady growth and market-average valuation.
🐻 Bear Case
- The strong bearish trend, confirmed by ADX and MACD, suggests further downside potential despite oversold RSI.
- High market volatility (VIX 30.61) and a declining S&P 500 could trigger broader market capitulation, dragging HCA lower.
- Failure to hold key support levels, particularly the Anchored VWAP at $425.84, could lead to a deeper correction.
🎯 Investor Action Plan — By Profile
Stay on the sidelines for now. Await a clear technical reversal signal, such as a reclaim of $480 with above-average volume, before considering a long entry. Set a tight stop-loss below $460.
Avoid initiating a new position until the strong bearish momentum subsides and the stock shows signs of bottoming. Consider scaling into a position if HCA tests the $445 (SMA200) or $425 (Anchored VWAP) levels and shows a bullish divergence on RSI.
If already holding, maintain your position, as the long-term fundamental thesis for HCA remains intact. For new capital, wait for a more favorable entry point, ideally below $460, to capitalize on the current market weakness without catching a falling knife.
❓ Investor FAQ — People Also Ask
Q: Why is HCA’s stock falling so sharply despite strong earnings and insider buying?
While HCA reports robust earnings and sees insider confidence, the stock is caught in a powerful bearish trend, confirmed by ADX and MACD. This, coupled with high market volatility (VIX 30.61) and a declining S&P 500, has overshadowed positive fundamentals, leading to the recent 11.5% monthly decline.
Q: What are the key technical levels to watch for a potential reversal or further downside?
Watch for HCA to reclaim $480, which would fill the nearest bearish FVG and move above the Volume Profile’s POC. On the downside, critical support lies at the Bollinger Lower Band ($460.29), the 200-day SMA ($445.07), and the Anchored VWAP ($425.84). A break below these could signal further capitulation.
Q: Does the extremely low RSI (1.5) guarantee a bounce soon?
An RSI of 1.5 indicates extreme oversold conditions, making a bounce highly probable in the near term. However, it does not guarantee a sustained reversal, especially when strong bearish momentum (high ADX, negative MACD) persists. Traders should wait for price confirmation, such as a break above short-term resistance, before acting.
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute investment advice. All investment decisions should be made with due diligence and consultation with a qualified financial advisor. Past performance is not indicative of future results. The author may hold positions in the securities mentioned.
All active positions and their real-time performance are tracked on our Investment Log.
#HCA #HCAHealthcare #USStocks #HealthcareStocks #StockAnalysis #TechnicalAnalysis #MarketVolatility